Liquid Handling Systems Market worth 3.74 Billion USD by 2022

The liquid handling systems market is expected to reach USD 3.74 Billion by 2022 from USD 2.65 Billion in 2017, at a CAGR of 7.2%. Factors driving the growth of this market include the global growth in the biotechnology and pharmaceutical industries, rising demand for high-throughput screening (HTS), increasing focus on data precision and accuracy, and technological innovations to develop novel liquid handling systems.

Pipettes are estimated to dominate the market in 2017

On the basis of products, the liquid handling systems market is segmented into pipettes, burettes, consumables, microplate reagent dispensers, microplate washers, liquid handling workstations, software, and other products. The pipettes segment is expected to dominate the global liquid handling systems market in 2017. Efficient performance, reliability, great level of precision, adaptability across multiple applications, and minimal maintenance needs are key drivers increasing the demand for pipettes.

Download the PDF Brochure for More Details@ http://bit.ly/2IRkOGd

Electronic systems are estimated to command the largest market share in 2017

The liquid handling systems market is segmented by type into electronic systems, automated systems, and manual systems. In 2017, the electronic systems segment is expected to account for the largest share of the liquid handling systems market, by type. High accuracy and reproducibility offered by electronic liquid handling systems, coupled with their lower cost compared to automated systems are factors driving its adoption among end users like pharmaceutical and biotechnology companies, research laboratories, and academic institutes.

North America expected to account for the major share of the market in 2017

Based on region, the liquid handling systems market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the liquid handling systems market in 2017 on account of growth in the biotechnology and pharmaceutical industries, rising prevalence of chronic diseases, and higher investments in genomics and proteomics research in the region.

Key players in the liquid handling systems market include Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Eppendorf AG (Germany), Tecan Group Ltd. (Switzerland), Gardner Denver Medical (Germany), Mettler-Toledo International Inc. (U.S.), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Sartorius AG (Germany), Corning Incorporated (U.S.), Gilson, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Qiagen N.V. (Germany), Lonza Group Ltd (Switzerland), Brooks Automation, Inc. (U.S.), Integra Holding AG (Switzerland), Endress+Hauser AG (Switzerland), Labcyte Inc. (U.S.), BioTek Instruments, Inc. (U.S.), TTP Labtech Ltd (U.K.), Metrohm AG (Switzerland), BRAND GMBH + CO KG (Germany), Tomtec, Inc. (U.S.), Hudson Robotics, Inc. (U.S.), and Orochem Technologies Inc. (U.S.).

Target Audience for this Report:

• Genomics and proteomics associations
• Drug discovery and development research centers
• Hospitals and diagnostic laboratories
• Research & consulting firms
• Distributors of liquid handling products
• Contract manufacturers of protein liquid handling systems and consumables
• Research institutes and clinical research organizations (CROs)
• Venture capitalists
• Government associations

Read More Detailed Article on "Liquid Handling System Market - Forecast to 2022", Here..!

Neurovascular Devices/Interventional Neurology - Vital Factors of the Global Industry Growth

[193 Pages Report] The global interventional neurology/neurovascular devices market is estimated to reach USD 2.62 Billion by 2021, at a CAGR of 8.6% during the forecast period. 

The large patient population base with target diseases, ongoing product development & commercialization, favorable medical reimbursements, expansion of healthcare infrastructure across emerging markets, and growing market demand for effective neurovascular devices are some key factors driving the growth of the market.

Key Market Restraints:

# Stringent Regulations

# Dearth of Skilled Neurosurgeons

Key Market Opportunities:

# Increasing Research Activities in the Field of Neurovascular Therapies

# Rising Demand for Minimally Invasive Neurosurgical Procedures

Ongoing Clinical Studies:

# Embolization Coiling Procedures

# Carotid Artery Stenting Procedures

# Embolic Protection Procedures

# Flow Diversion Procedures

# Supporting Techniques

# Neurothrombectomy Procedures

Download the PDF Brochure for More Details@ http://bit.ly/2OiLeqf

On the basis of geography, this market is classified into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is the fastest-growing geographic segment in the neurovascular devices/interventional neurology market. The large market growth of this geographic segment can be attributed to the presence of a large patient population base for target diseases, rising awareness among neurosurgeons related to the benefits offered by interventional neurology devices, and ongoing government initiatives to modernize & expand healthcare infrastructure.
Product Launches and Enhancements is the Key Strategy Adopted by Leading Market Players to Foster their Growth in the Global Neurovascular Devices/Interventional Neurology Market
The key players in the neurovascular devices/interventional neurology market focused on various strategies such as product launches & enhancements; agreements and collaborations; strategic acquisitions; and expansions to increase market shares in the global market. Product launches & enhancements were the key strategies adopted by major industry players to achieve the desired market growth during 2013-2016. 

This strategy was mainly adopted by Stryker Corporation (U.S.), Medtronic plc (U.S.), Johnson & Johnson (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Abbott Laboratories (U.S.), Merit Medical Systems, Inc. (U.S.), W. L. Gore & Associates, Inc. (U.S.), and MicroPort Scientific Corporation (China). Apart from product launches & enhancements, many prominent players also adopted agreements & collaborations as the key growth strategy to strengthen market presence, enhance R&D capabilities, and to expand distribution networks to generate additional demand by sensitizing end users through an increase in availability of neurovascular products.

Target Audience

• Healthcare service providers (Hospitals and surgical centers)
• Non-government organizations
• Government regulatory authorities
• Research laboratories and academic institutes
• Clinical research organizations (CROs)
• Research and development companies
• Market research and consulting firms

Read the Detailed Article on "Neurovascular Devices/Interventional Neurology Market - Global Forecasts to 2021", Here..!

Topical Drug Delivery Market: Major Growth Drivers of the Global Industry

Formulations to grow at the highest CAGR during the forecast period.

Based on product type, the topical drug delivery market is segmented into formulations, and devices. Devices segment is projected to register the highest CAGR during the forecast period. Devices includes transdermal patches and transdermal gels.

Devices (Transdermal drug delivery) could replace the injectable mode of delivery required to deliver many new biologic drugs and vaccines. Factors like improved patient compliance, noninvasive nature, elimination of hepatic first pass metabolism, enhancement of therapeutic efficiency, and maintenance of steady plasma level of the drug are contributing to the growth of the transdermal drug delivery devices market.

Download the PDF Brochure for More Details@ http://bit.ly/2ORqCog

The global topical drug delivery market is projected to reach USD 125.9 billion by 2021. Market growth can be attributed to factors such as rising prevalence of skin diseases, the convenience of topical drugs, high incidences of burns, rising incidence of diabetes, and growth in geriatric population. Product recalls and their negative impacts on the market are expected to restrict the adoption of topical drugs to a certain extent during the forecast period.

Growing prevalence for topical drug delivery and rapid growth in geriatric population are the major drivers for the market.

Topical drug delivery has the advantage of delivering drugs more selectively to a specific site. Moreover, the use of topical drugs helps avoid fluctuation in drug levels, improves compliance, and facilitates self-medication. As a result, the topical route is preferred over other routes of drug delivery for the treatment of many diseases/conditions. On the other hand, topical delivery involves painless administrations and minimal risk of infections. Considering these advantages, many pharmaceutical companies are developing and launching topical drugs for indications that were traditionally treated using oral or injectable drugs.

Aging is associated with decreased cellular function, which reduces the body’s natural ability to close and heal wounds. As a result, geriatric individuals are major end users of topical drugs for the treatment of wounds. Serious chronic wounds such as pressure ulcers are also very common in the elderly population. With growth in this population segment, the prevalence of several chronic diseases is expected to increase in the coming years, thus driving the demand for convenient drug delivery options, such as topical drug delivery.

However, negative impact of product recalls is restraining the market growth.

Read the Detailed Article@ 

https://www.marketsandmarkets.com/Market-Reports/topical-drug-delivery-market-124871717.html#

Human Microbiome Market - New Revenue Pockets | Global industry Forecasts Till 2025

Factors such as increased focus on human microbiome therapy, growing demand for human microbiomes as new validated targets for drug development, and the need for early disease detection and diagnosis are expected to drive the growth of the human microbiome market.

Restraints:

# Lack of Expertise and Detailed Research

# Barriers in Proving the Causal Link Between Dysbiosis and Disease

Opportunities:

# Investigational New Drug (IND) Requirements for Fecal Microbiota

# Increasing Collaborations Create Growth Opportunities

Challenge:

# Government Regulations

Burning Issues:

# Abundant Opportunities in the Human Microbiome Field and Tremendous Research Investments

# Development of Human Microbiome Therapeutic Products

Get More Details | Download the PDF Brochure@ http://bit.ly/2QBkCgK

In this report, the human microbiome market is broadly segmented into product, application, disease, and region while, the human microbiome research spending market is broadly segmented into product and technology.

Microbiome-based drugs are expected to see an increased demand in the future, because of the rise in the incidence of lifestyle diseases and associated side-effects of various therapies across the world. Significant growth in the human microbiome market will be mainly driven by the rise in awareness of its use in diseases such as diarrhea, diabetes, obesity, and autoimmune disorders. 

The need for early disease detection and diagnosis will also drive the use of microbiomes in molecular diagnostics. In addition, the representation of human microbiomes as validated targets for developing drugs and chemical entities will further boost growth in the market.

Advances in human microbiome-based diagnostic applications may offer a wide range of new technologies that will help in cost- and time-efficient disease diagnosis. With the introduction of microbiome techniques, the market will witness higher growth in the forecast period. 

The growing awareness on healthcare has fueled the demand for products such as probiotics, prebiotics, medical foods, which is driving the growth of the human microbiome market segment. The largest product segment in this market is probiotics, which is expected to grow at a quick pace in the coming years. Market players have heightened their focus on this segment, as a result of which products launches in this sector have increased. 

Read the Detailed Article@ 

https://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html

Europe is expected to be the largest contributor to the human microbiome market, owing to the rise in the lifestyle diseases and increased demand and awareness of prebiotics and probiotics. On the other hand North America has the fastest growth rate. This is due to, the probiotics market in this region which is expected to grow rapidly due to the general affinity of the U.S. population towards probiotic dietary supplements and the concept of preventive healthcare.

The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and Company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)